Pharmalucence traces its roots to CIS-US, Inc.  CIS-US was incorporated in 1985 to commercialize medical applications from isotopic technologies developed by its European parent company. 

In mid-2007, Pharmalucence was created via the management buy-out of CIS-US by three long-term employees who shared the vision to become the leading company in radiopharmaceutical supply and in so doing, establish an advanced drug production capability that could be leveraged as a contract manufacturing organization. 

Pharmalucence received approval of its first new product, the hepatobiliary imaging agent generic Mebrofenin, in 2008.

In July 2009, Pharmalucence was notified of FDA approval for its generic Sestamibi, an agent used in the majority of heart imaging studies. 

With its new product line additions and the on-going demand for its traditional products, Pharmalucence has initiated investment in its production infrastructure during 2010.  A new corporate headquarters and drug manufacturing facility is being constructed with occupancy planned in 2013.  This new facility will support Pharmalucence product supply and provide the foundation to make the organization a key source of contract production of injectable drugs.

PharmaGap is pursuing pre-clinical development of its lead drug candidate, GAP-107B8, for use in treating cancer.  GAP-107B8 selectively targets Protein Kinase C (PKC), a validated target for potentially treating certain types and stages of cancer. GAP-107B8’s compelling bioactivity, efficacy and excellent safety profile has been demonstrated in vitro and in animal models. GAP-107B8 has been developed by way of computer assisted rational drug design.

PharmaGap’s researchers have deep knowledge of cell signaling pathways involved in the onset of cancer, particularly those controlled by the PKC family.  Work is also being pursued developing a pipeline of drug modulators targeting PKC isoforms important in other disease conditions, such as heart disease and diabetes. 

PharmaGap’s business model strategy is to out-license its drug compounds targeting PKC prior to commencement of later-stage clinical trials in humans. Management and the board are pursuing this strategy to maximize sustainable value for shareholders. PharmaGap shares trade on Toronto’s TSX-Venture Exchange.

Founded in 1999, PharmaGap is a spin-out from the National Research Council of Canada, Canada’s premier biological research organization. The Company’s development activities take place in labs and offices located in Ottawa, Ontario, Canada.

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs.